Investigation of PAX3/7-FKHR fusion genes and IGF2 gene expression in rhabdomyosarcoma tumors

Growth Hormone and IGF Research

Volumn 22, Issue 6, 2012, Pages 245-249

  de Souza, Robson Ramos ^a   Oliveira, Indhira Dias ^a   Caran, Eliana Maria Monteiro ^a   Alves, Maria Teresa de Seixas ^a   Abib, Simone ^a   Toledo, Silvia Regina Caminada ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Gene fusion; IGF2 gene; PAX3 7 FKHR; Rhabdomyosarcoma; Soft tissue tumors

Indexed keywords

SOMATOMEDIN B; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR PAX3; TRANSCRIPTION FACTOR PAX7;

ARTICLE; CHILD; CLINICAL ARTICLE; EMBRYONAL RHABDOMYOSARCOMA; FEMALE; FKHR GENE; FUSION GENE; GENE EXPRESSION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IGF2 GENE; MALE; PAX3 GENE; PAX7 GENE; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; TUMOR CELL LINE;

ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ADOLESCENT; CELL LINE, TUMOR; CHILD; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR II; LUNG NEOPLASMS; MALE; ONCOGENE PROTEINS, FUSION; PAIRED BOX TRANSCRIPTION FACTORS; PAX7 TRANSCRIPTION FACTOR; RETROSPECTIVE STUDIES; RHABDOMYOSARCOMA; RHABDOMYOSARCOMA, EMBRYONAL;

EID: 84868483005     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2012.07.003     Document Type: Article

References (33)

1. Downing J.R., Khandekar A., Shurtleff S.A., et al. Multiplex RT-PCR assay for the differential diagnosis of alveolar rhabdomyosarcoma and Ewing's sarcoma. Am. J. Pathol. 1995, 146:626-634.
2. Anderson J., Gordon A., McNanus A., et al. Disruption of imprinted genes at chromosome region 11p15.5 in paediatric rhabdomyosarcoma. Neoplasia 1999, 1:340-348.
3. Davicioni E., Finckenstein F.G., Shahbazian V., et al. Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res. 2006, 66:6936-6946.
4. Dagher R., Helman L. Rhabdomyosarcoma: an Overview. Oncologist 1999, 4:34-44.
5. Mercado G.E., Barr F.G. Fusions involving PAX and FOX genes in the molecular pathogenesis of alveolar rhabdomyosarcoma: recent advances. Curr. Mol. Med. 2007, 7:47-61.
6. Laé M., Ahn E.H., Mercado G.E., et al. Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas. J. Pathol. 2007, 212:143-151.
7. Sorensen P.H., Lynch J.C., Qualman S.J., et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J. Clin. Oncol. 2002, 20:2672-2679.
8. Williamson D., Missiaglia E., de Reyniès A., et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J. Clin. Oncol. 2010, 13:2151-2158.
9. Bridge J.A., Liu J., Qualman S.J., et al. Genomic gains and losses are similar in genetic and histologic subsets of rhabdomyosarcoma, whereas amplification predominates in embryonal with anaplasia and alveolar subtypes. Genes Chromosomes Cancer 2002, 33:310-321.
10. Wexler L.H., Ladanyi M. Diagnosing Alveolar Rhabdomyosarcoma: morphology must be coupled with fusion confirmation. J. Clin. Oncol. 2010, 28(13):2126-2128.
11. Baird K., Davis S., Antonescu C.R., et al. Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res. 2005, 65:9226-9235.
12. Scotlandi K., Manara M.C., Nicoletti G., et al. Antitumor activity of the insulin-like growth factor-i receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res. 2005, 65:3868-3876.
13. Makawita S., Ho M., Durbin A.D., et al. Expression of insulin-like growth factor pathway proteins in rhabdomyosarcoma: IGF-2 expression is associated with translocation-negative tumors. Pediatr. Dev. Pathol. 2009, 12:127-135.
14. Lee O.H., Bae S.K., Bae M.H., et al. Identification of angiogenic properties of insulin-like growth factor II in in vitro angiogenesis models. Br. J. Cancer 2000, 82:385-391.
15. Pollak M.N., Schernhammer E.S., Hankinson S.E. Insulin-like growth factors and neoplasia. Nat. Rev. Cancer 2004, 4:505-518.
16. Zhang L., Wang C. Identification of a new class of PAX3-FKHR target promoters: a role of the PAX3 paired box DNA binding domain. Oncogene 2007, 26:1595-1605.
17. El-Badry O.M., Minniti C., Kohn E.C., et al. Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Differ. 1990, 1:325-331.
18. Yun K. A new marker for rhabdomyosarcoma: Insulin-like growth factor II. Lab. Invest. 1992, 67:653-664.
19. Wang W., Kumar P., Wang W., et al. Insulin-like Growth Factor II and PAX3-FKHR Cooperate in the Oncogenesis of Rhabdomyosarcoma. Cancer Res. 1998, 58:4426-4433.
20. Barr F.G., Chatten J., D'Cruz, et al. Molecular Assays for Chromosomal Translocations in the Diagnosis of Pediatric Soft Tissue Sarcomas. JAMA 1995, 273:553-557.
21. Dalla-Torre C.A., Yoshimoto M., Lee C.H., et al. Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma. BMC Cancer 2006, 237.
22. Helman L.J., Meltzer P. Mechanisms of sarcoma development. Nat. Rev. Cancer 2003, 9:685-694.
23. Barr F.G., Smith L.M., Lynch J.C., et al. Examination of Gene Fusion Status in Archival Samples of Alveolar Rhabdomyosarcoma Entered on the Intergroup Rhabdomyosarcoma Study-III Trial. J. Mol. Diagn. 2006, 8:202-208.
24. Davis R.J., Barr F.G. Fusion genes resulting from alternative chromosomal translocations are overexpressed by gene-specific mechanisms in alveolar rhabdomyosarcoma. Proc. Natl. Acad. Sci. 1997, 94:8047-8051.
25. Anderson J., Gordon T., McManus A., et al. Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome?; UK Children's Cancer Study Group (UKCCSG) and the UK Cancer Cytogenetics Group. Br. J. Cancer 2001, 6:831-835.
26. Parham D.M. Pathologic classification of rhabdomyosarcomas and correlations with molecular studies. Mod. Pathol. 2001, 5:506-514. [Review].
27. Barr F.G., Smith L.M., Lynch J.C., et al. Examination of gene fusion status in archival samples of alveolar rhabdomyosarcoma entered on the Intergroup Rhabdomyosarcoma Study-III trial: a report from the Children's Oncology Group. J Mol. Diagn. 2006, 2:202-208.
28. Sayer A.A., Syddall H., O'Dell S.D., et al. Polymorphism of the IGF2 gene, birth weight and grip strength in adult men. Age Ageing 2002, 31:468-470.
29. Zhan S., Shapiro D.N., Helman L.J. Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. J. Clin. Invest. Jul 1994, 94:445-448.
30. Hahn H., Wojnowski L., Specht K., et al. Patched Target IGF2 is Indispensable for the Formation of Medulloblastoma and Rhabdomyosarcoma. J. Biol. Chem. 2000, 37:28341-28344.
31. Wachtel M., Schäfer B.W. Targets for cancer therapy in childhood sarcomas. Cancer Treat. Rev. 2010, 36:318-327.
32. Sachdev D., Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol. Cancer Ther. 2007, 6:1-12.
33. Linabery A.M., Ross J.A. Childhood and adolescent cancer survival in the US by race and ethnicity for the diagnostic period 1975-1999. Cancer 2008, 113:2575-2596.